一名同时患有膀胱癌和前列腺癌的患者中，2-[F]FDG和[Ga]Ga-PSMA PET/CT的分子影像结果不一致。
Discordant Molecular Imaging Findings with 2-[F]FDG and [Ga]Ga-PSMA PET/CT in a Patient with Both Bladder and Prostate Cancer.
作者信息
Mahalik Aparna, Jaleel Jasim, Sagar Sambit, Khan Dikhra, Raju Shobhana, Kumar Rakesh
机构信息
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029 India.
出版信息
Nucl Med Mol Imaging. 2024 May;58(3):150-151. doi: 10.1007/s13139-024-00839-4. Epub 2024 Jan 29.
Abstract
The prevalence of double primary prostate and bladder cancer is not uncommon. Though both share a common pathway of malignant transformation, they bear to differ in the case of 2-[F]FDG PET/CT and [Ga]Ga-PSMA uptake. We present a case of double primary cancer involving the bladder and prostate, where the prostatic primary showed intense [Ga]Ga-PSMA uptake with non-avid skeletal and pulmonary metastases, which showed intense 2-[F]FDG uptake, thus showing discordance due to different clonal origins.
摘要
原发性前列腺癌和膀胱癌同时存在的情况并不罕见。尽管两者都有共同的恶性转化途径，但在2-[F]FDG PET/CT和[Ga]Ga-PSMA摄取方面存在差异。我们报告一例同时累及膀胱和前列腺的双原发性癌病例，其中前列腺原发性肿瘤显示强烈的[Ga]Ga-PSMA摄取，而骨骼和肺部转移灶无摄取，这些转移灶显示强烈的2-[F]FDG摄取，因此由于不同的克隆起源而表现出不一致。
相似文献
1
Discordant Molecular Imaging Findings with 2-[F]FDG and [Ga]Ga-PSMA PET/CT in a Patient with Both Bladder and Prostate Cancer.一名同时患有膀胱癌和前列腺癌的患者中，2-[F]FDG和[Ga]Ga-PSMA PET/CT的分子影像结果不一致。
Nucl Med Mol Imaging. 2024 May;58(3):150-151. doi: 10.1007/s13139-024-00839-4. Epub 2024 Jan 29.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
A prospective intra-individual comparison of [Ga]Ga-PSMA-11 PET/CT, [Ga]Ga-NODAGA PET/CT, and [Tc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases.一种前瞻性个体内比较研究：用于前列腺癌骨转移放射性核素成像的[Ga]Ga-PSMA-11 PET/CT、[Ga]Ga-NODAGA PET/CT 和[Tc]Tc-MDP 骨闪烁显像。
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):134-142. doi: 10.1007/s00259-020-04867-y. Epub 2020 May 18.
4
Prostate-specific membrane antigen PET versus [Tc]Tc-MDP bone scan for diagnosing bone metastasis in prostate cancer: a head-to-head comparative meta-analysis.前列腺特异性膜抗原正电子发射断层扫描与[锝]锝-亚甲基二膦酸盐骨扫描在诊断前列腺癌骨转移中的应用：一项直接比较的Meta分析
Front Med (Lausanne). 2024 Sep 25;11:1451565. doi: 10.3389/fmed.2024.1451565. eCollection 2024.
5
Exploratory analysis of 64 CuCl 2 PET-CT imaging in carcinoma prostate and its comparison with 68 Ga-PSMA-11 and 18 F-FDG PET-CT.64CuCl2 PET-CT 显像在前列腺癌中的探索性分析及其与 68Ga-PSMA-11 和 18F-FDG PET-CT 的比较。
Nucl Med Commun. 2023 Oct 1;44(10):910-923. doi: 10.1097/MNM.0000000000001744. Epub 2023 Aug 14.
6
Head-To-Head Comparison of Ga-PSMA-11 PET/CT and Tc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis.镓-PSMA-11 PET/CT 与 Tc-MDP 骨显像用于前列腺癌患者骨转移检测的头对头比较：一项荟萃分析。
AJR Am J Roentgenol. 2022 Sep;219(3):386-395. doi: 10.2214/AJR.21.27323. Epub 2022 Apr 20.
7
Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study.镓-前列腺特异性膜抗原是一种用于肝细胞癌成像的新型正电子发射断层扫描-计算机断层扫描示踪剂：一项前瞻性试点研究。
J Nucl Med. 2019 Feb 1;60(2):185-191. doi: 10.2967/jnumed.118.214833. Epub 2018 Jul 12.
8
Ga-PSMA PET/CT Versus F-FDG PET/CT for Imaging of Hepatocellular Carcinoma.镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描与氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描用于肝细胞癌成像的比较
Mol Imaging Radionucl Ther. 2021 Jun 3;30(2):79-85. doi: 10.4274/mirt.galenos.2021.92053.
9
The diagnostic accuracy of Ga-PSMA PET/CT versus Tc-MDP bone scintigraphy for identifying bone metastases in persons with prostate cancer: A systematic review.镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描（Ga-PSMA PET/CT）与锝-亚甲基二膦酸盐骨闪烁显像（Tc-MDP）在前列腺癌患者骨转移诊断中的准确性：一项系统评价。
J Med Imaging Radiat Sci. 2023 Sep;54(3):545-555. doi: 10.1016/j.jmir.2023.04.005. Epub 2023 May 20.
10
[Clinical Value of Dual Tracer PET Imaging With Ga-PSMA and F-FDG in Patients With Metastatic Prostate Cancer].[镓-前列腺特异性膜抗原（Ga-PSMA）与氟代脱氧葡萄糖（F-FDG）双示踪剂PET成像在转移性前列腺癌患者中的临床价值]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024 Sep 20;55(5):1063-1070. doi: 10.12182/20240960201.
本文引用的文献
1
Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for F-FDG Imaging of PSMA-Suppressed Tumors.具有神经内分泌基因特征的前列腺癌中葡萄糖转运体和己糖激酶的差异表达：PSMA 抑制肿瘤 F-FDG 成像的机制观点。
J Nucl Med. 2020 Jun;61(6):904-910. doi: 10.2967/jnumed.119.231068. Epub 2019 Dec 5.
2
Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations.18F-氟代脱氧葡萄糖 PET/CT 对前列腺癌的影像学评估：效用与局限性。
Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1(0 1):S5-10. doi: 10.1007/s00259-013-2361-7. Epub 2013 Feb 22.
3
Double primary cancers of the prostate and bladder: a literature review.前列腺和膀胱双原发癌：文献综述
Clin Prostate Cancer. 2004 Sep;3(2):83-6. doi: 10.3816/cgc.2004.n.016.
4
Prostate stem cell antigen is overexpressed in human transitional cell carcinoma.前列腺干细胞抗原在人移行细胞癌中过度表达。
Cancer Res. 2001 Jun 15;61(12):4660-5.
5
Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers.
Anticancer Res. 1999 Nov-Dec;19(6B):5415-7.
6
Coincidence of bladder and prostate cancer.
J Urol. 1997 Jan;157(1):65-7.
7
Prostatic involvement in bladder cancer. Prostate mapping in 20 cystoprostatectomy specimens.
Cancer. 1986 Nov 1;58(9):2096-102. doi: 10.1002/1097-0142(19861101)58:9<2096::aid-cncr2820580922>3.0.co;2-0.
8
Carcinogenic properties of pharmaceutical agents evaluated in the IARC Monographs programme.
Carcinogenesis. 1991 Oct;12(10):1751-66. doi: 10.1093/carcin/12.10.1751.
Zotero 插件